Helus Pharma announced that Eric So, Interim Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York taking place June 2-4. The fireside chat is scheduled for Thursday, June 4, at 2:35 p.m. EDT and will be webcast live, with a replay available on the company’s investor relations website.
Company focus on novel serotonergic agonists
Helus Pharma (Nasdaq: HELP, Cboe CA: HELP) is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company operates in Canada, the United States, the United Kingdom, and Ireland.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/gnwcq-2026-6-1-helus-pharma-to-participate-in-the-jefferies-global-healthcare-conference-in-new-york